Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 33 citing articles:

Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics
Tosin Akinsipe, Rania Mohamedelhassan, Ayuba Akinpelu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 17
Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4
Ana Santiso, Ákos Heinemann, Julia Kargl
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 388-413
Open Access | Times Cited: 16
Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
Minchuan Zhang, Kong‐Peng Lam, Shengli Xu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer
Mustafa Emre Gedik, Özge Saatci, Nathaniel Oberholtzer, et al.
Cancer Research (2024) Vol. 84, Iss. 9, pp. 1475-1490
Open Access | Times Cited: 12
The next frontier in immunotherapy: potential and challenges of CAR-macrophages
Jing Li, Ping Chen, Wenxue Ma
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth
Sandeep Artham, Patrick K. Juras, Aditi Goyal, et al.
Science Advances (2024) Vol. 10, Iss. 39
Open Access | Times Cited: 6
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
Loredana Cifaldi, Ombretta Melaiu, Roberto Giovannoni, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Fc Gamma Receptor Polymorphisms in Antibody Therapy: Implications for Bioassay Development to Enhance Product Quality
Julianne D. Twomey, S. Elizabeth George, Bao-Lin Zhang
Antibody Therapeutics (2025) Vol. 8, Iss. 2, pp. 87-98
Open Access
NK cells in renal cell carcinoma and its implications for CAR-NK therapy
Xinwei Li, Yuanpeng Zhang, Yuzhong Ye, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer
Ruoxin Du, Changqing Cao, Fan Dong, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Immunoregulatory natural killer cells
Kevin Roe
Clinica Chimica Acta (2024) Vol. 558, pp. 117896-117896
Closed Access | Times Cited: 3
Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review
Chaozhi Tang, Yuling Zhang
Pathology - Research and Practice (2024) Vol. 262, pp. 155518-155518
Closed Access | Times Cited: 3
Metronomic chemotherapy in cancer treatment: new wine in an old bottle
Huailiang Wu, Han-Xing Zhou, Limin Chen, et al.
Theranostics (2024) Vol. 14, Iss. 9, pp. 3548-3564
Open Access | Times Cited: 2
Natural Killer Cells in Cancers of Respiratory System and Their Applications in Therapeutic Approaches
Maryam Dokhanchi, Atefe Panahipoor Javaherdehi, Mohammad Raad, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 11
Open Access | Times Cited: 1
Natural killer cells in tumor immunotherapy
Dongyao Wang, Haiming Wei
Cancer Biology and Medicine (2023), pp. 1-6
Open Access | Times Cited: 4
Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms
Jennifer N. Saultz, Folashade Otegbeye
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Immune landscape of hepatocellular carcinoma: From dysregulation of the immune responses to the potential immunotherapies
Atieh Pourbagheri‐Sigaroodi, Majid Momeny, Reza Yazdani, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 5
Closed Access | Times Cited: 1
Multimodal MRI for Estimating Her-2 Gene Expression in Endometrial Cancer
Li Xiwei, Shifeng Tian, Changjun Ma, et al.
Bioengineering (2023) Vol. 10, Iss. 12, pp. 1399-1399
Open Access | Times Cited: 3
Cancer Immunotherapy Via Stem Cell-Derived NK Cells
Fatemeh Hosseini, Mohammad Ahmadvand, Roya Karimi, et al.
Immunotherapy (2023) Vol. 15, Iss. 12, pp. 963-973
Closed Access | Times Cited: 2
Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer
Mustafa Emre Gedik, Özge Saatci, Nathaniel Oberholtzer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Exploring cellular immunotherapy platforms in multiple myeloma
Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27892-e27892
Open Access
Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC
Feifei Li, Youyang Shi, Mei Ma, et al.
Journal of Pharmaceutical Analysis (2024) Vol. 14, Iss. 10, pp. 100977-100977
Open Access
Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal Cancers
Wen‐Chi Wu, Chien-Fu Hsu, Ming‐Huang Chen, et al.
Research Square (Research Square) (2024)
Open Access
Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance
Hanjing Peng, Yukinori Endo, Wen Jin Wu
Cancers (2024) Vol. 16, Iss. 13, pp. 2367-2367
Open Access
A high affinity monoclonal antibody against HLA-E-VL9 enhances natural killer cell anti-tumor killing
Joyce K. Hwang, Daniel J. Marston, Daniel Wrapp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Page 1 - Next Page

Scroll to top